Lndip-Trio Tablet is a combination antihypertensive medication containing Telmisartan 40mg, Cilnidipine 10mg, and Chlorthalidone 12.5mg, formulated to manage essential hypertension effectively. Telmisartan, an angiotensin II receptor blocker (ARB), works by inhibiting the vasoconstrictive effects of angiotensin II, thereby reducing peripheral vascular resistance and lowering blood pressure. Cilnidipine, a calcium channel blocker of the dihydropyridine class, exerts dual action by blocking L-type and N-type calcium channels, resulting in vasodilation and decreased sympathetic nerve activity, which further aids in blood pressure control. Chlorthalidone, a thiazide-like diuretic, promotes natriuresis and diuresis by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, reducing plasma volume and peripheral resistance. The synergistic effect of this triple combination provides comprehensive blood pressure reduction through multiple mechanisms, improving cardiovascular outcomes and reducing the risk of stroke, myocardial infarction, and heart failure. Lndip-Trio is indicated for patients with hypertension inadequately controlled by monotherapy or dual therapy. It should be used under medical supervision with regular monitoring of blood pressure, electrolytes, renal function, and potential adverse effects such as hypotension, electrolyte imbalance, or renal impairment.